Abbott Laboratories (ABT) reported first-quarter earnings that met analyst expectations, but the stock fell 6% as investors reacted negatively to a significant cut in full-year profitability guidance. The company posted sales of nearly $11.2 billion, an 8% year-over-year increase, with adjusted earnings per share matching forecasts at $1.15. Notably, Abbott’s medical devices segment excelled, achieving a 13% sales growth, driven by strong performances in electrophysiology and diabetes care.
The market’s disappointment stemmed from Abbott’s revised 2026 earnings guidance, which was lowered to $5.38 to $5.58 per share from a previous estimate of $5.55 to $5.80. This adjustment reflects anticipated share dilution following the acquisition of Exact Sciences, which is expected to impact profitability despite strong underlying sales growth projections.
For market professionals, the key takeaway is that while Abbott’s core business remains robust, the lowered guidance signals caution. This could present a buying opportunity for those who believe in the company’s long-term growth trajectory, especially given the continued strength in its medical devices segment.
Source: fool.com